{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:36:13Z","timestamp":1790537773191,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/gt.2017.45","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T14:41:05Z","timestamp":1496241665000},"page":"514-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Therapeutic approaches for spinal muscular atrophy (SMA)"],"prefix":"10.1038","volume":"24","author":[{"given":"M","family":"Scoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R S","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"BFgt201745_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72400 specimens. Eur J Hum Genet 2012; 20: 27\u201332.","journal-title":"Eur J Hum Genet"},{"key":"BFgt201745_CR2","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/pd.4459","volume":"34","author":"WK MacDonald","year":"2014","unstructured":"MacDonald WK, Hamilton D, Kuhle S . SMA carrier testing: a meta-analysis of differences in test performance by ethnic group. Prenat Diagn 2014; 34: 1219\u20131226.","journal-title":"Prenat Diagn"},{"key":"BFgt201745_CR3","doi-asserted-by":"crossref","unstructured":"Wadman RI, Bosboom WM, van der Pol WL, van den Berg LH, Wokke JH, Iannaccone ST et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev 2012: Cd006281.","DOI":"10.1002\/14651858.CD006281.pub4"},{"key":"BFgt201745_CR4","doi-asserted-by":"crossref","unstructured":"Wadman RI, Bosboom WM, van der Pol WL, van den Berg LH, Wokke JH, Iannaccone ST et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev 2012: Cd006282.","DOI":"10.1002\/14651858.CD006282.pub4"},{"key":"BFgt201745_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123\u2013126.","journal-title":"Nature"},{"key":"BFgt201745_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","volume":"21","author":"PN Porensky","year":"2012","unstructured":"Porensky PN, Mitrpant C, McGovern VL, Bevan AK, Foust KD, Kaspar BK et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 2012; 21: 1625\u20131638.","journal-title":"Hum Mol Genet"},{"key":"BFgt201745_CR7","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017\u20133026.","journal-title":"Lancet"},{"key":"BFgt201745_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00109-008-0388-1","volume":"86","author":"LK Tsai","year":"2008","unstructured":"Tsai LK, Tsai MS, Ting CH, Li H . Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med (Berlin, Germany) 2008; 86: 1243\u20131254.","journal-title":"J Mol Med (Berlin, Germany)"},{"key":"BFgt201745_CR9","doi-asserted-by":"publisher","first-page":"5ra12","DOI":"10.1126\/scitranslmed.3000208","volume":"1","author":"ML Hastings","year":"2009","unstructured":"Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, Barthel L et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Trans Med 2009; 1: 5ra12.","journal-title":"Sci Trans Med"},{"key":"BFgt201745_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007; 117: 659\u2013671.","journal-title":"J Clin Invest"},{"key":"BFgt201745_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.21449","volume":"64","author":"HL Narver","year":"2008","unstructured":"Narver HL, Kong L, Burnett BG, Choe DW, Bosch-Marce M, Taye AA et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol 2008; 64: 465\u2013470.","journal-title":"Ann Neurol"},{"key":"BFgt201745_CR12","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","volume":"18","author":"L Garbes","year":"2009","unstructured":"Garbes L, Riessland M, Holker I, Heller R, Hauke J, Trankle C et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 2009; 18: 3645\u20133658.","journal-title":"Hum Mol Genet"},{"key":"BFgt201745_CR13","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","volume":"19","author":"M Riessland","year":"2010","unstructured":"Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 2010; 19: 1492\u20131506.","journal-title":"Hum Mol Genet"},{"key":"BFgt201745_CR14","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","volume":"18","author":"VB Mattis","year":"2009","unstructured":"Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL . Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum Mol Genet 2009; 18: 3906\u20133913.","journal-title":"Hum Mol Genet"},{"key":"BFgt201745_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, NY) 2014; 345: 688\u2013693.","journal-title":"Science (New York, NY)"},{"key":"BFgt201745_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.1837","volume":"11","author":"J Palacino","year":"2015","unstructured":"Palacino J, Swalley SE, Song C, Cheung AK, Shu L, Zhang X et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol 2015; 11: 511\u2013517.","journal-title":"Nat Chem Biol"},{"key":"BFgt201745_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28: 271\u2013274.","journal-title":"Nat Biotechnol"},{"key":"BFgt201745_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI41615","volume":"120","author":"MA Passini","year":"2010","unstructured":"Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010; 120: 1253\u20131264.","journal-title":"J Clin Invest"},{"key":"BFgt201745_CR19","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Trans Med 2010; 2: 35ra42.","journal-title":"Sci Trans Med"},{"key":"BFgt201745_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.24332","volume":"77","author":"SI Duque","year":"2015","unstructured":"Duque SI, Arnold WD, Odermatt P, Li X, Porensky PN, Schmelzer L et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol 2015; 77: 399\u2013414.","journal-title":"Ann Neurol"},{"key":"BFgt201745_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187\u20131196.","journal-title":"Mol Ther"},{"key":"BFgt201745_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1124\/jpet.107.123000","volume":"322","author":"T Bordet","year":"2007","unstructured":"Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007; 322: 709\u2013720.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFgt201745_CR23","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","volume":"59","author":"AN Calder","year":"2016","unstructured":"Calder AN, Androphy EJ, Hodgetts KJ . Small molecules in development for the treatment of spinal muscular atrophy. J Med Chem 2016; 59: 10067\u201310083.","journal-title":"J Med Chem"},{"key":"BFgt201745_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/WNL.59.4.609","volume":"59","author":"M Kinali","year":"2002","unstructured":"Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002; 59: 609\u2013610.","journal-title":"Neurology"},{"key":"BFgt201745_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","volume":"18","author":"M Pane","year":"2008","unstructured":"Pane M, Staccioli S, Messina S, D'Amico A, Pelliccioni M, Mazzone ES et al. Daily salbutamol in young patients with SMA type II. Neuromusc Disord 2008; 18: 536\u2013540.","journal-title":"Neuromusc Disord"},{"key":"BFgt201745_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jmg.2007.051177","volume":"45","author":"C Angelozzi","year":"2008","unstructured":"Angelozzi C, Borgo F, Tiziano FD, Martella A, Neri G, Brahe C . Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Clin Genet 2008; 45: 29\u201331.","journal-title":"J Clin Genet"},{"key":"BFgt201745_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmg.2010.080366","volume":"47","author":"FD Tiziano","year":"2010","unstructured":"Tiziano FD, Lomastro R, Pinto AM, Messina S, D'Amico A, Fiori S et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 2010; 47: 856\u2013858.","journal-title":"J Med Genet"},{"key":"BFgt201745_CR28","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1460-9568.2007.05780.x","volume":"26","author":"E Hedlund","year":"2007","unstructured":"Hedlund E, Hefferan MP, Marsala M, Isacson O . Cell therapy and stem cells in animal models of motor neuron disorders. Eur J Neurosci 2007; 26: 1721\u20131737.","journal-title":"Eur J Neurosci"},{"key":"BFgt201745_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/14712598.8.2.137","volume":"8","author":"VE Koliatsos","year":"2008","unstructured":"Koliatsos VE, Xu L, Yan J . Human stem cell grafts as therapies for motor neuron disease. Expert Opin Biol Ther 2008; 8: 137\u2013141.","journal-title":"Expert Opin Biol Ther"},{"key":"BFgt201745_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.tins.2008.01.006","volume":"31","author":"M Suzuki","year":"2008","unstructured":"Suzuki M, Svendsen CN . Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 2008; 31: 192\u2013198.","journal-title":"Trends Neurosci"},{"key":"BFgt201745_CR31","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1172\/JCI35432","volume":"118","author":"S Corti","year":"2008","unstructured":"Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008; 118: 3316\u20133330.","journal-title":"J Clin Invest"},{"key":"BFgt201745_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(02)00835-8","volume":"110","author":"H Wichterle","year":"2002","unstructured":"Wichterle H, Lieberam I, Porter JA, Jessell TM . Directed differentiation of embryonic stem cells into motor neurons. Cell 2002; 110: 385\u2013397.","journal-title":"Cell"},{"key":"BFgt201745_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nbt1063","volume":"23","author":"XJ Li","year":"2005","unstructured":"Li XJ, Du ZW, Zarnowska ED, Pankratz M, Hansen LO, Pearce RA et al. Specification of motoneurons from human embryonic stem cells. Nat Biotechnol 2005; 23: 215\u2013221.","journal-title":"Nat Biotechnol"},{"key":"BFgt201745_CR34","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1126\/science.1158799","volume":"321","author":"JT Dimos","year":"2008","unstructured":"Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (New York, NY) 2008; 321: 1218\u20131221.","journal-title":"Science (New York, NY)"},{"issue":"Pt 2","key":"BFgt201745_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/brain\/awp318","volume":"133","author":"S Corti","year":"2010","unstructured":"Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010; 133 (Pt 2): 465\u2013481.","journal-title":"Brain"},{"key":"BFgt201745_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1373\/clinchem.2014.231019","volume":"61","author":"JL Taylor","year":"2015","unstructured":"Taylor JL, Lee FK, Yazdanpanah GK, Staropoli JF, Liu M, Carulli JP et al. Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin Chem 2015; 61: 412\u2013419.","journal-title":"Clin Chem"},{"key":"BFgt201745_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jnr.10109","volume":"67","author":"C Cifuentes-Diaz","year":"2002","unstructured":"Cifuentes-Diaz C, Faille L, Goudou D, Schachner M, Rieger F, Angaut-Petit D . Abnormal reinnervation of skeletal muscle in a tenascin-C-deficient mouse. J Neurosci Res 2002; 67: 93\u201399.","journal-title":"J Neurosci Res"},{"key":"BFgt201745_CR38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.neulet.2008.10.107","volume":"449","author":"S Kariya","year":"2009","unstructured":"Kariya S, Mauricio R, Dai Y, Monani UR . The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy. Neurosci Lett 2009; 449: 246\u2013251.","journal-title":"Neurosci Lett"},{"key":"BFgt201745_CR39","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz MS et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 2008; 17: 2552\u20132569.","journal-title":"Hum Mol Genet"},{"key":"BFgt201745_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","volume":"69","author":"GZ Mentis","year":"2011","unstructured":"Mentis GZ, Blivis D, Liu W, Drobac E, Crowder ME, Kong L et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 2011; 69: 453\u2013467.","journal-title":"Neuron"},{"key":"BFgt201745_CR41","doi-asserted-by":"publisher","first-page":"34635","DOI":"10.1038\/srep34635","volume":"6","author":"E Szunyogova","year":"2016","unstructured":"Szunyogova E, Zhou H, Maxwell GK, Powis RA, Francesco M, Gillingwater TH et al. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci Rep 2016; 6: 34635.","journal-title":"Sci Rep"},{"key":"BFgt201745_CR42","first-page":"932","volume":"26","author":"MT Khairallah","year":"2017","unstructured":"Khairallah MT, Astroski J, Custer SK, Androphy EJ, Franklin CL, Lorson CL . SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of Spinal muscular atrophy. Hum Mol Genet 2017; 26: 932\u2013941.","journal-title":"Hum Mol Genet"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201745","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.45","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/gt201745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:28:59Z","timestamp":1648560539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFgt201745"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.45","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"assertion":[{"value":"8 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FM is involved as principal investigator in the following clinical trials: nusinersen (SHINE, sponsored by Ionis and Biogen); olesoxime (OLEOS, sponsored by Roche). He has participated in scientific advisory board activities for Roche; Biogen and Avexis, and is also a member of the Pfizer rare disease scientific advisory board. MS is involved as sub-investigator in SHINE clinical trial and is principal investigator in OLEOS clinical trial. RFS is involved as principal investigator in the following SMA clinical trials: nusinersen (CS3A, ENDEAR, CHERISH, NURTURE and SHINE, sponsored by Ionis and Biogen) and CK-2127107 (CY 5021 study, sponsored by Cytokinetics and Astellas). He has participated in scientific advisory board activities for Ionis, Biogen, Roche, Novartis and AveXis; has served on the DSMB for the Roche RG7800 and AveXis AVXS-101 phase 1 study; and has served as an advisor to CureSMA (US), the SMA Foundation (US), SMA REACH (UK) and SMA Europe. EM is involved as principal investigator in the following clinical trials: nusinersen (SHINE, sponsored by Ionis and Biogen); olesoxime (OLEOS, sponsored by Roche). He has participated in scientific advisory board activities for Ionis, Roche; Biogen and Avexis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}